<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04493918</url>
  </required_header>
  <id_info>
    <org_study_id>18-04-0389</org_study_id>
    <nct_id>NCT04493918</nct_id>
  </id_info>
  <brief_title>Effectivity of Mesenchymal Stem Cell on Vertebral Bone Defect Due to Mycobaterium Tuberculosis Infection</brief_title>
  <official_title>Effectivity of Local Implantation of the Mesenchymal Stem Cell on Vertebral Bone Defect Due to Mycobaterium Tuberculosis Infection (Clinical Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ahmad Jabir Rahyussalim</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indonesia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the effectiveness of locally implantation of mesenchymal stem cell on&#xD;
      vertebral bone defects due to infection of mycobacterium tuberculosis. there are controlled&#xD;
      participants who receives placebo and patients who receives implantation of MSc&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Mesenchymal Stem Cell are implanted in Spinal Tuberculosis patient. MSC has inflammatory&#xD;
      effect and the ability to form into new bone.&#xD;
&#xD;
      In Spinal Tuberculosis, the spread of bacteria is commonly hematogenous, where the focus of&#xD;
      infection is at the anterior part of the vertebrae near the subchondral bone. The infection&#xD;
      process continues, where the necrotic casseous fragments formed into local abcess that may&#xD;
      spread to the sorrounding area.&#xD;
&#xD;
      Patient with spinal tuberculosis who receives Anti TB Drug, is planned to undergo&#xD;
      debridement, spinal stabilization. After thorough debridement, patient who fall into control&#xD;
      group receives normal saline injection, patients who fall into treatment group will receive&#xD;
      Mesenchymal Stem Cell.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 21, 2017</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Participants do not know which treatment they receives. Outcome assessor is a radiologist</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Vertebral bony fusion</measure>
    <time_frame>1 Year</time_frame>
    <description>trabecular bone on xray and CT scan</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Spinal Tuberculosis</condition>
  <condition>Mesenchymal Stem Cell</condition>
  <arm_group>
    <arm_group_label>MSC Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mesenchymal Stem Cell + NaCl 0,9% 2ml</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Mesenchymal Stem cell + Nacl 0.9%</intervention_name>
    <description>Patient who undergo surgery, debridement, decompression and posterior stabilization injection with Nacl 0.9% 2 ml + MSC 30 million unit</description>
    <arm_group_label>MSC Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>NaCl 0.9%</intervention_name>
    <description>Patient who undergo surgery, debridement, decompression and posterior stabilization injection with Nacl 0.9% 2 ml</description>
    <arm_group_label>MSC Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinicoradiologically diagnoses Spinal Tuberculosis&#xD;
&#xD;
          -  receives Anti TB drugs&#xD;
&#xD;
          -  minimun destruction 1/3 vertebral body&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patient under 15 years old&#xD;
&#xD;
          -  reject to be included in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ahmad Jabir Rahyussalim, PhD</last_name>
    <phone>+62811819466</phone>
    <email>rahyussalim71@ui.ac.id</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tri Kurniawati, Mrs</last_name>
    <phone>+628121134311</phone>
    <email>trie3k@ui.ac.id</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cipto Mangunkusumo Hospital</name>
      <address>
        <city>Jakarta Pusat</city>
        <state>DKI Jakarta</state>
        <zip>10430</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmad Jabir Rahyussalim, MD,PhD,SpOT</last_name>
      <phone>+62811819466</phone>
      <email>rahyussalim71@ui.ac.id</email>
    </contact>
    <contact_backup>
      <last_name>Trie K Kurniawati, SSi</last_name>
      <phone>+628121134311</phone>
      <email>trie3k@ui.ac.id</email>
    </contact_backup>
    <investigator>
      <last_name>Ahmad Jabir Rahyussalim, MD,PhD,SpOT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 28, 2020</study_first_submitted>
  <study_first_submitted_qc>July 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2020</study_first_posted>
  <last_update_submitted>July 30, 2020</last_update_submitted>
  <last_update_submitted_qc>July 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Indonesia University</investigator_affiliation>
    <investigator_full_name>Ahmad Jabir Rahyussalim</investigator_full_name>
    <investigator_title>Dr. dr. Rahyussalim SpOT(K)</investigator_title>
  </responsible_party>
  <keyword>Mycobacterium tuberculosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Latent Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Spinal</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

